Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_assertion type Assertion NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_head.
- NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_assertion description "[Also apolipoproteins show major changes, with an increase in apolipoprotein A-I, A-IV, B, C, and E. Particularly the changes in apo C-II, which is an activator of the enzyme lipoprotein lipase (LPL), and apo C-III, an inhibitor of LPL, with an increase of the C-III to C-II ratio, might contribute to the impaired lipoprotein catabolism in NS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_provenance.
- NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_assertion evidence source_evidence_literature NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_provenance.
- NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_assertion SIO_000772 15827892 NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_provenance.
- NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_assertion wasDerivedFrom befree-20140225 NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_provenance.
- NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_assertion wasGeneratedBy ECO_0000203 NP682300.RARYKPaSaXajnFBCeCNCJXfs9osLJhd26AxoRaUZG8YS8130_provenance.